Literature DB >> 8436440

Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines.

K McLaughlin1, G Coren, J Masters, R Brown.   

Abstract

Proteins can be detected by South-western analyses of human tumour-cell extracts binding to double-stranded oligonucleotide DNA treated in vitro with the chemotherapeutic drug cis-diamminedichloroplatinum (II) (CDDP), but not to untreated DNA. The relative molecular masses of proteins binding to the CDDP-treated double-stranded oligonucleotide are 25, 48 and 97 kDa. The binding activity of 2 of the CDDP-damage-recognition proteins, of relative molecular mass 48 and 97 kDa, is greater in a CDDP-resistant human ovarian tumour cell line than in the parental sensitive line. South-western analysis of a panel of human bladder cell lines and CDDP-sensitive testicular cell lines show consistent patterns of CDDP-damage-recognition proteins within each cell type, however with differences between the 2 cell types. Binding of the proteins to CDDP-damaged DNA and the altered binding activity detected in tumour cell lines suggests that alteration in damage-recognition proteins could play a role in tumour response to CDDP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436440     DOI: 10.1002/ijc.2910530423

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  1 in total

1.  Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.

Authors:  M W Sark; H Timmer-Bosscha; C Meijer; D R Uges; W J Sluiter; W H Peters; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.